A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA

Protocol Number
PRAN 16-52

To Learn More Call
201-510-0910

Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910

Prospective Collection of Samples for Research

Protocol Number
05035

To Learn More Call
201-510-0910

A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents

Sponsor
Xcovery Holding Company

Protocol Number
X396-CLI-301

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

Prospective, Longitudinal, Non-Interventional study of Disease Burden and treatment of patients with low-risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Receving ET- Directed Therapy

Sponsor
Incyte

Protocol Number
INCB-MA-MF-401(MOST)

To Learn More Call
201-510-0910